One-Day liver cancer treatment could cut hospital time in half

NCT ID NCT06618300

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a lung safety check saves time and money without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Yttrium-90 (Y90) radioembolization
What this could lead to: If successful, this could make liver cancer treatment faster and more convenient by cutting the procedure from two days to one, reducing patient travel and healthcare costs.
What could go wrong: This is a small early feasibility study with only 30 patients, so results may not apply to everyone. There is also a risk that skipping the lung shunt calculation could lead to complications in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

UNC Hospitals

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.